Showing 1 - 10 of 422
condition for designing effective policies is to identify who drives antibiotic treatment decisions, physicians or patient …
Persistent link: https://www.econbiz.de/10013218285
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D investments...
Persistent link: https://www.econbiz.de/10012833741
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012843430
This paper provides insights into the determinants of bargaining power and how they affect drug prices. Our data show that drug prices vary across buyers and time periods. We estimate a structural bargaining model where drug suppliers and buyers engage in bilateral bargaining over drug prices....
Persistent link: https://www.econbiz.de/10012845687
there is substantial variation in the quality of physicians, as measured by patients’ post-assignment mortality, in the …
Persistent link: https://www.econbiz.de/10014082234
We analyze prescription behavior of physicians in the public and private sector. We study two major diseases for which … private sector physicians are more likely to prescribe the expensive medication. The result holds after controlling for … our cases, we further find that the same physicians prescribe different medication when working in different sectors …
Persistent link: https://www.econbiz.de/10014263219
In the pharmaceutical industry, firms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps firms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug development...
Persistent link: https://www.econbiz.de/10012832198
-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …
Persistent link: https://www.econbiz.de/10013316907
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046
When managers have objectives beyond maximizing monetary profits, inefficiencies may arise. An increase in competition may then force managers to improve the productivity of the firm in order to ensure survival. While this hypothesis has received ample theoretical attention, empirical evidence...
Persistent link: https://www.econbiz.de/10012179827